Neuland Paliperidone Palmitate Neuland Paliperidone Palmitate

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Drugs in Development News & Deals for 1,2-Benzisoxazole, 4H-pyrido[1,2-a]pyrimidin-4-one deriv.

    Client Email Product

    1,2-Benzisoxazole, 4H-pyrido[1,2-a]pyrimidin-4-one deriv.

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    44
    US DMFs Filed

    US DMFs Filed

    26
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    10
    Other Suppliers

    Other Suppliers

    24
    API REF. PRICE (USD / KG)
    43,164

    API Market Place

    10
    INTERMEDIATES
    9
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    41
    Europe

    Europe

    41
    Canada

    Canada

    3
    Australia

    Australia

    14
    South Africa

    South Africa

    7
    Uploaded Dossiers

    Uploaded Dossiers

    34
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    4,817.00

    Annual Reports

    311.00

    FDF Market Place

    5
    EXCIPIENTS
    145
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    26
    REF STANDARD

    EDQM

    0

    USP

    6

    JP

    0

    Other Listed Suppliers

    7
    SERVICES
    3
    left grey arrow
    right gray arrow
    • TABLET, EXTENDED RELEASE;ORAL - 1.5MG
    • TABLET, EXTENDED RELEASE;ORAL - 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
    • TABLET, EXTENDED RELEASE;ORAL - 3MG
    • TABLET, EXTENDED RELEASE;ORAL - 6MG
    • TABLET, EXTENDED RELEASE;ORAL - 9MG
    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Paliperidone Extended-Release Tablets Obtains Drug Registration Approval

    Details:

    Paliperidone Extended Release tablets is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.


    Lead Product(s): Paliperidone

    Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 14, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lupin Launches Paliperidone Extended-Release Tablets in The United States

    Details:

    Paliperidone Extended Release Tablets is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.


    Lead Product(s): Paliperidone

    Therapeutic Area: Psychiatry/Psychology Product Name: Invega-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 20, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Lupin Receives Approval From U.S. FDA for Paliperidone Extended-Release Tablets

    Details:

    Paliperidone Extended Release Tablets is a central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism which isused to treat schizophrenia.


    Lead Product(s): Paliperidone

    Therapeutic Area: Psychiatry/Psychology Product Name: Invega-Generic

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 30, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Interquim Paliperidone RM

    Access Virtual Booth

    Contact Supplier

    View Presentation

    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search